Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 in sensitive relapse SCLC
NCT00412880Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of BI-2536 in small cell lung cancer (SCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Objective Tumor Response up to 40 weeks. Started Feb 2007; status: completed.
02
Drugs
BI-2536
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00412880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412880.